摘要
对于局部晚期食管鳞状细胞癌,新辅助治疗联合手术切除已成为标准治疗方案。以程序性死亡[蛋白]-1和程序性死亡[蛋白]配体-1抑制剂为代表的免疫治疗的加入,为食管鳞状细胞癌的新辅助治疗注入新活力。目前大量临床试验正在开展、探索中,为临床病理医师的诊断带来新挑战。笔者结合国内外相关报道及临床诊断问题,从病理学角度出发,详述新辅助免疫治疗前后病理学评估的研究进展,旨在提高临床病理学诊断水平,为进一步优化综合治疗策略提供参考。
For locally advanced esophageal squamous cell carcinoma(EScC),neoadjuvant therapy combined with surgery has become the standard treatment schedule.The application of immunotherapy,represented by programmed death-1 and programmed death-ligand 1 inhibitors,has injected new vitality into neoadjuvant therapy for ESCC.At present,a large number of clinical trials are being carried out and explored,which brings new challenges to the diagnosis of clinical pathologists.Combined with the latest researches at home and abroad and clinical diagnosis problems,the authors summarize the relevant problems and progress of pathological evaluation before and after neoadjuvant immunotherapy from the perspective of pathology,in order to improve the level of clinical pathological diagnosis and provide reference for further optimizing the comprehensive treatment strategy.
作者
侯英勇
蒋冬先
谭黎杰
Hou Yingyong;Jiang Dongxian;Tan Lijie(Department of Pathology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Thoracic Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2023年第3期316-321,共6页
Chinese Journal of Digestive Surgery
基金
国家自然科学基金青年基金(81702372)
上海市临床专科建设项目(shslczdzk01302)。
关键词
食管肿瘤
鳞状细胞癌
新辅助免疫治疗
疗效
病理学评估
Esophageal neoplasms
Squamous cell carcinoma
Neoadjuvant immunotherapy
Efficacy
Pathologicassessment
